TP53 and B-cell chronic lymphocytic leukemia: Interim analyses of ALPINE study demonstrated the PFS superiority of zanubrutinib versus Ib for unselected patients with R/R CLL, which was sustained in all major sub-groups including those with TP53 aberrancy, HR 0.53 (95% CI 0.31–0.88) [63].